Search Results

You are looking at 171 - 180 of 496 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Axel Grothey and Alan P. Venook

Hematology and Medical Oncology, Mayo Clinic Cancer Center, who described this study at the NCCN 23rd Annual Conference. “I believe we have the first important changes in adjuvant chemotherapy since 2004,” Dr. Grothey said, referring to the adoption of 6

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars

-positive, T1 breast cancer (category 1 with tamoxifen; category 2A with an aromatase inhibitor). If adjuvant chemotherapy is indicated after breast-conserving surgery, radiation should be given after chemotherapy is completed. 73 , 74 This recommendation is

Full access

Maurie Markman

methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy . Cancer Res 1980 ; 40 : 3665 – 3668 . 6 Durand RE . Flow cytometry studies of intracellular adriamycin in multicell spheroids

Full access

Thomas A. D'Amico

-based treatment guidelines. 2 Advantages of thoracoscopic lobectomy compared with thoracotomy include less postoperative pain, 6 , 7 better pulmonary function, 7 , 8 shorter hospitalization, 4 – 11 and improved delivery of adjuvant chemotherapy to eligible

Full access

Nora M. Hansen, Sally Anne Scherer, and Seema Khan

but refused by the patient. The ASCO3 measure recommends that patients younger than 70 years with stage III (T1cN0), stage II, and stage I breast cancer receive adjuvant chemotherapy begun within 120 days of diagnosis. Among the institution’s subset

Full access

Joseph A. Roscoe, Gary R. Morrow, Jane T. Hickok, Karen M. Mustian, and Abhay R. Shelke

-Trill M Hakes TB Kaufman RJ . Nonpharmacologic factors in the development of posttreatment nausea with adjuvant chemotherapy for breast cancer . Cancer 1988 ; 61 : 379 – 385 . 13 Haut MW Beckwith B Laurie JA Klatt N . Postchemotherapy

Full access

Heather Hampel

. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis . Eur J Cancer 2009 ; 45 : 1890 – 1896 . 3. Jarvinen HJ Renkonen-Sinisalo L Aktan-Collan K . Ten

Full access

Angela M. Davies, Philip C. Mack, Primo N. Lara Jr., Derick H. Lau, Kathleen Danenberg, Paul H. Gumerlock, and David R. Gandara

advanced or metastatic NSCLC . J Clin Oncol 2003 ; 21 : 2658 – 2663 . 36 Mitsudomi T Yatabe Y Tada H . Lack of predictive value of p53, p27, Bcl2, HER2/neu, EGFR alterations for efficacy of postoperative adjuvant chemotherapy consisting of

Full access

Brigette A. Davis, Jenerius A. Aminawung, Maysa M. Abu-Khalaf, Suzanne B. Evans, Kevin Su, Rajni Mehta, Shi-Yi Wang, and Cary P. Gross

-related genes and 5 reference genes) to generate a recurrence score (RS). Studies have shown that the RS is both prognostic—it correlates with 10-year risk of distant recurrence—and predictive of the degree to which adjuvant chemotherapy will reduce the risk of

Full access

Ronald C. Chen, William U. Shipley, Jason A. Efstathiou, and Anthony L. Zietman

cystectomy and adjuvant chemotherapy . Urology 2009 ; 73 : 833 – 837 . 28. Hagan MP Winter KA Kaufman DS . RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation